Hey guys I just wanted to create a thread discussing some of the differences between Ryoncil and Jakafi trial results prior to approval/rejection from the fda. From what I understand Novartis did a single arm trial with only a small number of patients prior to approval due to it demonstrating approx 69% overall response rate vs around 30% in the standard care group however there were significant adverse events such as thrombocytopenia, anaemia and cytomegalovirus etc. I get that Jakafi was already approved for other conditions and has a defined MOA but how can you turn down Ryoncil and not Jakafi with their relative safety profiles. Why can’t mesoblast perform a retrospective study on their patients in Japan and use that to support efficacy etc
- Forums
- ASX - By Stock
- Ruxolitinib vs Ryoncil
Hey guys I just wanted to create a thread discussing some of the...
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.31 |
Change
0.150(13.0%) |
Mkt cap ! $1.490B |
Open | High | Low | Value | Volume |
$1.15 | $1.33 | $1.15 | $25.26M | 19.99M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 161000 | $1.30 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.31 | 50400 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 161000 | 1.300 |
6 | 101986 | 1.295 |
6 | 226866 | 1.290 |
4 | 70613 | 1.285 |
5 | 137074 | 1.280 |
Price($) | Vol. | No. |
---|---|---|
1.310 | 50400 | 2 |
1.315 | 2007 | 1 |
1.320 | 40992 | 3 |
1.325 | 20772 | 3 |
1.330 | 139522 | 8 |
Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online